story of the week
Efgartigimod Shows Efficacy and Safety in Generalised Myasthenia Gravis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety, Efficacy, and Tolerability of Efgartigimod in Patients With Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial
Lancet Neurol 2021 Jul 01;20(7)526-536, JF Howard, V Bril, T Vu, C Karam, S Peric, T Margania, H Murai, M Bilinska, R Shakarishvili, M Smilowski, A Guglietta, P Ulrichts, T Vangeneugden, K Utsugisawa, J Verschuuren, R MantegazzaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.